{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.7","value":"11.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"221"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Luspatercept (ACE-536) was administered subcutaneously (SC) at a starting dose level of 1 mg/kg once every 21 days. Participants could be dose-titrated to 1.25 mg/kg, but the maximum total dose should not exceed 120 mg, total dose per administration during the Treatment Period, the Long-term Treatment Period, and Open-Label Treatment Period. BSC = Best Supportive Care","id":"OG000","title":"Luspatercept + BSC"},{"description":"Placebo (normal saline) was administered subcutaneously (SC) in volumes to match active treatment once every 21 days. BSC = Best Supportive Care","id":"OG001","title":"Placebo + BSC"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All randomized participants with available PK measurements for Luspatercept","reportingStatus":"POSTED","timeFrame":"Blood serum samples taken pre-dose and on Days 1, 22, 64, 85, 106, 127, 169, 211, 253, 295, 337","title":"Pharmacokinetic (PK) Parameters: Bayesian Estimate of Elimination Half-life (t1/2)","type":"SECONDARY","unitOfMeasure":"days"}